Certara Overview

  • Year Founded
  • 1979

Year Founded

  • Status
  • Public

  • Employees
  • 1,550

Employees

  • Stock Symbol
  • CERT

Stock Symbol

  • Investments
  • 22

  • Share Price
  • $10.68
  • (As of Thursday Closing)

Certara General Information

Description

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

Contact Information

Website
www.certara.com
Formerly Known As
Tripos
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 4 Radnor Corporate Center
  • Suite 350
  • Radnor, PA 19087
  • United States
+1 (415)
Primary Industry
Drug Delivery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 4 Radnor Corporate Center
  • Suite 350
  • Radnor, PA 19087
  • United States
+1 (415)

Certara Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Certara Stock Performance

As of 19-Nov-2026, Certara’s stock price is $10.68. Its current market cap is $1.63B with 153M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.68 $11.18 $4.45 - $12.61 $1.63B 153M 2.6M -$0.42

Certara Financials Summary

As of 30-Sep-2026, Certara has a trailing 12-month revenue of $426M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,518,003 1,532,993 1,787,969 2,842,719
Revenue 425,760 418,838 385,148 354,337
EBITDA 85,486 102,517 72,369 23,844
Net Income (64,336) (1,595) (12,051) (55,357)
Total Assets 1,414,918 1,556,582 1,575,104 1,563,140
Total Debt 298,226 305,985 311,897 302,567
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Certara Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Certara‘s full profile, request access.

Request a free trial

Certara Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug
Drug Delivery
Radnor, PA
1,550 As of 2026

Moscow, Russia
 

Milford, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Certara Competitors (14)

One of Certara’s 14 competitors is Atlant Clinical, a Corporate Backed or Acquired company based in Moscow, Russia.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Atlant Clinical Corporate Backed or Acquired Moscow, Russia
SeraCare Formerly PE-Backed Milford, MA
Metrum Research Group Corporation Simsbury, CT
BPS Bioscience Corporation San Diego, CA
Heron Therapeutics Formerly VC-backed Cary, NC
You’re viewing 5 of 14 competitors. Get the full list »

Certara Patents

Certara Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4762480-A1 Graphical user interface for providing automated, real-time interactive word processing assistance to a user Pending 17-Aug-2023
US-20250060864-A1 Graphical user interface for providing automated, real-time interactive word processing assistance to a user Pending 17-Aug-2023
WO-2025038725-A1 Graphical user interface for providing automated, real-time interactive word processing assistance to a user Inactive 17-Aug-2023
EP-4762492-A1 Machine-learning models to create, update, validate, and/or assess the comprehensiveness of a mechanistic model of biological systems Pending 17-Aug-2023
US-20250061961-A1 Machine-learning models to create, update, validate, and/or assess the comprehensiveness of a mechanistic model of biological systems Pending 17-Aug-2023 G16B5/00
To view Certara’s complete patent history, request access »

Certara Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Certara Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Certara‘s full profile, request access.

Request a free trial

Certara Investments & Acquisitions (22)

Certara’s most recent deal was a Merger/Acquisition with ChemAxon for . The deal was made on 01-Oct-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ChemAxon 01-Oct-2024 Merger/Acquisition Enterprise Systems (Healthcare)
Applied BioMath 12-Dec-2023 Merger/Acquisition Drug Discovery
Formedix 10-Oct-2023 Merger/Acquisition Enterprise Systems (Healthcare)
Drug Interaction Solutions 20-Jun-2023 Merger/Acquisition Other Healthcare Technology Systems
Vyasa Analytics 28-Dec-2022 Merger/Acquisition Media and Information Services (B2B)
You’re viewing 5 of 22 investments and acquisitions. Get the full list »

Certara ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

15.08 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Health Care IT Services

Subindustry

of 50

Rank

Percentile

To view Certara’s complete esg history, request access »

Certara Exits (3)

Certara’s most recent exit was on 30-Apr-2002 from Signase. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Signase 30-Apr-2002 Completed
  • 2 buyers
Signase 01-May-2000 Completed
  • 3 buyers
Arena Pharmaceuticals 22-Feb-1999 Later Stage VC Completed
  • 5 buyers
To view Certara’s complete exits history, request access »

Certara Affiliates

Subsidiaries (6)

Name Industry Location Year Founded
Pinnacle 21 Radnor, PA 2011
ChemAxon Budapest, Hungary 1998
Analytica Laser London, United Kingdom 1997
Pharsight Mountain View, CA 1995
Drug Interaction Solutions Seattle, WA 1990
You’re viewing 5 of 6 affiliates. Get the full list.  »

Certara FAQs

  • When was Certara founded?

    Certara was founded in 1979.

  • Where is Certara headquartered?

    Certara is headquartered in Radnor, PA.

  • What is the size of Certara?

    Certara has 1,550 total employees.

  • What industry is Certara in?

    Certara’s primary industry is Drug Delivery.

  • Is Certara a private or public company?

    Certara is a Public company.

  • What is Certara’s stock symbol?

    The ticker symbol for Certara is CERT.

  • What is the current stock price of Certara?

    As of 19-Nov-2026 the stock price of Certara is $10.68.

  • What is the current market cap of Certara?

    The current market capitalization of Certara is $1.63B.

  • What is Certara’s current revenue?

    The trailing twelve month revenue for Certara is $426M.

  • Who are Certara’s competitors?

    Atlant Clinical, SeraCare, Metrum Research Group, BPS Bioscience, and Heron Therapeutics are some of the 14 competitors of Certara.

  • What is Certara’s annual earnings per share (EPS)?

    Certara’s EPS for 12 months was -$0.42.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process